{
    "id": 725,
    "fullName": "MTOR S2215Y",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MTOR S2215Y lies within the PI3K/PI4K domain of the mTOR protein (UniProt.org). S2215Y results in constitutive activation of Mtor signaling and increased cell proliferation in culture (PMID: 20190810).",
            "references": [
                {
                    "id": 374,
                    "pubMedId": 20190810,
                    "title": "Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20190810"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2475,
        "geneSymbol": "MTOR",
        "terms": [
            "MTOR",
            "FRAP",
            "FRAP1",
            "FRAP2",
            "RAFT1",
            "RAPT1",
            "SKS"
        ]
    },
    "variant": "S2215Y",
    "createDate": "06/13/2014",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": {
        "id": 145491,
        "transcript": "NM_004958",
        "gDna": "chr1:g.11124516G>T",
        "cDna": "c.6644C>A",
        "protein": "p.S2215Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4593,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD5363 inhibited proliferation of transformed human cell lines overexpressing MTOR S2215Y in culture (PMID: 26490311).",
            "molecularProfile": {
                "id": 828,
                "profileName": "MTOR S2215Y"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4623,
                    "pubMedId": 26490311,
                    "title": "Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26490311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7462,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Apitolisib (GDC-0980) inhibited Mtor activation in transformed cells over expressing MTOR S2215Y in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 828,
                "profileName": "MTOR S2215Y"
            },
            "therapy": {
                "id": 750,
                "therapyName": "GDC-0980",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7455,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torin 1 inhibited Mtor activation in transformed cells over expressing MTOR S2215Y in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 828,
                "profileName": "MTOR S2215Y"
            },
            "therapy": {
                "id": 2247,
                "therapyName": "Torin 1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4600,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY294002 inhibited proliferation of transformed human cell lines overexpressing MTOR S2215Y in culture (PMID: 26490311).",
            "molecularProfile": {
                "id": 828,
                "profileName": "MTOR S2215Y"
            },
            "therapy": {
                "id": 1062,
                "therapyName": "LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4623,
                    "pubMedId": 26490311,
                    "title": "Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26490311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4603,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cell lines overexpressing MTOR S2215Y demonstrated reduced sensitivity to Alpelisib (BYL719) -induced growth inhibition in culture (PMID: 26490311).",
            "molecularProfile": {
                "id": 828,
                "profileName": "MTOR S2215Y"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4623,
                    "pubMedId": 26490311,
                    "title": "Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26490311"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4606,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cell lines overexpressing MTOR S2215Y demonstrated reduced sensitivity to Afinitor (everolimus)-induced growth inhibition in culture (PMID: 26490311).",
            "molecularProfile": {
                "id": 828,
                "profileName": "MTOR S2215Y"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4623,
                    "pubMedId": 26490311,
                    "title": "Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26490311"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 726,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing MTOR S2215Y were sensitive to Rapamune (sirolimus) (PMID: 20190810).",
            "molecularProfile": {
                "id": 828,
                "profileName": "MTOR S2215Y"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5672,
                "name": "large intestine cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 374,
                    "pubMedId": 20190810,
                    "title": "Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20190810"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7461,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) inhibited Mtor activation in transformed cells over expressing MTOR S2215Y in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 828,
                "profileName": "MTOR S2215Y"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7487,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a endometrial cancer cell line harboring MTOR S2215Y demonstrated hypersensitivity to Rapamune (sirolimus) induced growth inhibition in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 828,
                "profileName": "MTOR S2215Y"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7482,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) inhibited foci formation in transformed cells over expressing MTOR S2215Y in culture (PMID: 26432419).",
            "molecularProfile": {
                "id": 828,
                "profileName": "MTOR S2215Y"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6364,
                    "pubMedId": 26432419,
                    "title": "Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432419"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 828,
            "profileName": "MTOR S2215Y",
            "profileTreatmentApproaches": [
                {
                    "id": 2843,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "MTOR S2215Y"
                },
                {
                    "id": 693,
                    "name": "mTOR Inhibitor",
                    "profileName": "MTOR S2215Y"
                },
                {
                    "id": 2844,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "MTOR S2215Y"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 145491,
            "transcript": "NM_004958",
            "gDna": "chr1:g.11124516G>T",
            "cDna": "c.6644C>A",
            "protein": "p.S2215Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 145493,
            "transcript": "XM_017000900",
            "gDna": "chr1:g.11112893G>T",
            "cDna": "c.6644C>A",
            "protein": "p.S2215Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 145492,
            "transcript": "XM_005263438",
            "gDna": "chr1:g.11124516G>T",
            "cDna": "c.6644C>A",
            "protein": "p.S2215Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}